Peptide functionalized LNPs as an alternative to ADCs
Antibody-drug conjugates have transformed cancer treatment, but the ones used against lung cancer carry a serious, often fatal side effect: interstitial lung disease. Peptide-functionalized LNPs offer an intriguing alternative; they are far less immunogenic, faster and cheaper to produce, and lack the structures thought to bring on ILD in these patients.